MX2023002362A - Tratamiento de cáncer de pulmón de células no pequeñas con mutaciones en el receptor del factor de crecimiento epidérmico (egfr). - Google Patents
Tratamiento de cáncer de pulmón de células no pequeñas con mutaciones en el receptor del factor de crecimiento epidérmico (egfr).Info
- Publication number
- MX2023002362A MX2023002362A MX2023002362A MX2023002362A MX2023002362A MX 2023002362 A MX2023002362 A MX 2023002362A MX 2023002362 A MX2023002362 A MX 2023002362A MX 2023002362 A MX2023002362 A MX 2023002362A MX 2023002362 A MX2023002362 A MX 2023002362A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- lung cancer
- egfr mutations
- small lung
- egfr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063069748P | 2020-08-25 | 2020-08-25 | |
| PCT/IB2021/057794 WO2022043895A2 (en) | 2020-08-25 | 2021-08-25 | Treatment of non-small lung cancer with egfr mutations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002362A true MX2023002362A (es) | 2023-05-19 |
Family
ID=80352814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002362A MX2023002362A (es) | 2020-08-25 | 2021-08-25 | Tratamiento de cáncer de pulmón de células no pequeñas con mutaciones en el receptor del factor de crecimiento epidérmico (egfr). |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12528869B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4204455A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023539589A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230053686A (cg-RX-API-DMAC10.html) |
| CN (1) | CN116194141A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021330539A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3192922A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL300854A (cg-RX-API-DMAC10.html) |
| JO (1) | JOP20230039A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2023002362A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022043895A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230174677A1 (en) * | 2021-11-16 | 2023-06-08 | Janssen Biotech, Inc. | Use of Approved Bispecific EGFR and Met Specific Antibody Drug Product to Treat Non-Small Cell Lung Cancer (NSCLCL) |
| CN119790073A (zh) * | 2022-06-30 | 2025-04-08 | 詹森生物科技公司 | 使用抗EGFR/抗Met抗体治疗胃癌或食道癌 |
| WO2024108193A2 (en) * | 2022-11-18 | 2024-05-23 | Epibiologics, Inc. | Degradation of cmet using a bispecific binding agent |
| CN116284335A (zh) * | 2023-03-17 | 2023-06-23 | 云南中医药大学 | Egfr基因突变体的检测方法及应用 |
| WO2025158277A1 (en) * | 2024-01-22 | 2025-07-31 | Janssen Biotech, Inc. | Use of amivantamab to treat head and neck cancer |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| AU2005250484B2 (en) | 2004-06-04 | 2011-08-11 | Genentech, Inc. | EGFR mutations |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| DK1999154T3 (da) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| CN101952312A (zh) | 2007-07-31 | 2011-01-19 | 米迪缪尼有限公司 | 多特异性表位结合蛋白及其应用 |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| EP3904391B1 (en) | 2010-03-10 | 2024-07-10 | Genmab A/S | Monoclonal antibodies against c-met |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| CA2832971C (en) | 2011-04-15 | 2016-04-12 | Esco Corporation | Replaceable wear parts for an earth-working roll |
| US9574010B2 (en) | 2011-11-04 | 2017-02-21 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| KR102373193B1 (ko) * | 2012-11-21 | 2022-03-10 | 얀센 바이오테크 인코포레이티드 | 이중특이성 EGFR/c-Met 항체 |
| US20170275367A1 (en) | 2012-11-21 | 2017-09-28 | Janssen Biotech, Inc. | Bispecific EGFR/C-Met Antibodies |
| EP3029067A1 (en) | 2014-12-01 | 2016-06-08 | Deutsches Krebsforschungszentrum | Use of blocking-reagents for reducing unspecific T cell-activation |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| BR112019010020A2 (pt) | 2016-11-17 | 2019-08-20 | Univ Texas | compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20 |
| WO2020102647A1 (en) | 2018-11-15 | 2020-05-22 | Invenra Inc. | Multivalent receptor-clustering agonist antibody constructs and antigen binding proteins |
| MX2021010265A (es) | 2019-02-26 | 2021-09-23 | Janssen Biotech Inc | Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos. |
| MY208668A (en) | 2019-05-14 | 2025-05-23 | Janssen Biotech Inc | Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors |
| IL305700A (en) | 2021-03-09 | 2023-11-01 | Janssen Biotech Inc | Treatment of cancers lacking EFGR-activating mutations |
-
2021
- 2021-08-25 EP EP21860686.1A patent/EP4204455A4/en active Pending
- 2021-08-25 JP JP2023513309A patent/JP2023539589A/ja active Pending
- 2021-08-25 KR KR1020237009896A patent/KR20230053686A/ko active Pending
- 2021-08-25 CN CN202180052496.5A patent/CN116194141A/zh active Pending
- 2021-08-25 WO PCT/IB2021/057794 patent/WO2022043895A2/en not_active Ceased
- 2021-08-25 IL IL300854A patent/IL300854A/en unknown
- 2021-08-25 US US17/411,158 patent/US12528869B2/en active Active
- 2021-08-25 CA CA3192922A patent/CA3192922A1/en active Pending
- 2021-08-25 AU AU2021330539A patent/AU2021330539A1/en active Pending
- 2021-08-25 MX MX2023002362A patent/MX2023002362A/es unknown
-
2023
- 2023-02-23 JO JOJO/P/2023/0039A patent/JOP20230039A1/ar unknown
-
2025
- 2025-11-14 US US19/389,439 patent/US20260070993A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JOP20230039A1 (ar) | 2023-02-23 |
| WO2022043895A8 (en) | 2023-03-09 |
| CA3192922A1 (en) | 2022-03-03 |
| AU2021330539A1 (en) | 2023-05-04 |
| US20260070993A1 (en) | 2026-03-12 |
| AU2021330539A9 (en) | 2023-07-13 |
| EP4204455A4 (en) | 2024-10-16 |
| WO2022043895A2 (en) | 2022-03-03 |
| US12528869B2 (en) | 2026-01-20 |
| WO2022043895A3 (en) | 2022-06-09 |
| EP4204455A2 (en) | 2023-07-05 |
| JP2023539589A (ja) | 2023-09-15 |
| IL300854A (en) | 2023-04-01 |
| KR20230053686A (ko) | 2023-04-21 |
| CN116194141A (zh) | 2023-05-30 |
| US20220064306A1 (en) | 2022-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022043895A8 (en) | Treatment of non-small cell lung cancer with egfr mutations | |
| CL2019001353A1 (es) | Compuestos con actividad antitumoral contra células cancerígenas que portan mutaciones en el exón 20 de egfr o her2. | |
| JOP20220184A1 (ar) | علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14 | |
| MA42999B1 (fr) | Polythérapie contenant ivosidenib, cytarabine et daunorubicin ou idarubicin pour le traitement de la leucémie myéloïde aiguë | |
| PH12022551013A1 (en) | Pyridazinones as parp7 inhibitors | |
| ZA202001445B (en) | Exon 18 and/or exon 21 mutant egfr selective inhibitor | |
| ZA201907225B (en) | Treatment of her2 positive cancers | |
| WO2019197605A3 (en) | Drug combinations for use in the treatment of ras-mutant cancer | |
| EP4353320A3 (en) | Blood plasma and plasma fractions as therapy for tumor growth and progression | |
| NZ726365A (en) | Combinations for treating cancers | |
| BR112015024537A8 (pt) | uso de um ou mais (i) ciclofosfamida, (ii) metformina e (iii) pelo menos um outro agente no tratamento de câncer, combinação, ciclofosfamida, metformina ou um agente | |
| MX2025002424A (es) | Combinacion de dcc-3116 e inhibidores de la via mapkap para su uso en el tratamiento del cancer | |
| ZA202304093B (en) | Neuregulin-4 compounds and methods of use | |
| ZA202104679B (en) | L718 and/or l792 mutant treatment-resistant egfr inhibitor | |
| MX2021008834A (es) | Metodos de tratamiento del cancer de mama con tucatinib. | |
| MX2022002607A (es) | Metodos de tratamiento. | |
| BR112022017491A2 (pt) | Método para tratar indivíduos resistentes ao inibidor idh1 | |
| MX2023010633A (es) | Tratamiento de canceres que carecen de mutaciones activadoras de egfr. | |
| WO2023019186A3 (en) | Compositions and methods for treatment of cancer | |
| BR112023020562A2 (pt) | Métodos de tratamento de carcinoma pulmonar de células não pequenas com o uso de telisotuzumabe vedotina | |
| MX2020009829A (es) | Composiciones farmaceuticas de saposina c y metodos para tratar el cancer. | |
| WO2019032810A3 (en) | Methods and materials for identifying and treating bet inhibitor-resistant cancers | |
| WO2022245299A3 (en) | Anti-ceacam5/6 antigen-binding molecules and methods of treatment thereof | |
| GB2616163B (en) | 4'-substituted analogues of fisetin and their use in the treatment of cancer | |
| WO2024220666A3 (en) | Treatment of non-small cell lung cancer |